CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes mellitus

Trial Profile

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes mellitus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Glucose intolerance; Glucose metabolism disorders; Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 05 Oct 2015 Accrual to date is 0% according to United Kingdom Clinical Research Network record.
    • 11 Oct 2014 New source identified and integrated (European Clinical Trials Database record: 2013-002249-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top